Interpretation 139
Tier 2|
|
|
Variants
Interpretation
When mutated, HRAS can act as an oncogene, causing normal cells to become cancerous. Somatic HRAS mutations have been associated with some cases of bladder, thyroid and kidney cancers and in nevi. Based on clinical evidence in melanoma with the related family member NRAS, downstream pathway MEK inhibitors may be a feasible treatment strategy. The effectiveness of MEK inhibitors for HRAS-mutant thyroid and bladder cancer patients has not yet been investigated.
Citations
- Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi. Bender RP et a 2013 Modern pathology : an official journal of the United States and Canadian
- Nikiforov Y. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011 May;135(5):569-77
- Czerniak et al..Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol. 1992 Nov;23(11):1199-204
- Ascierto PA et al.. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56
Last updated: 2015-12-09 20:17:06 UTC